Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 17, 2018 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Successfully Completes Production of More Than 8,500 Vials of Ampligen for Commercial Sales and Expanded Clinical Programs

ORLANDO, Fla., April 17, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in...
April 04, 2018 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Expands Ampligen Early Access Programme to Canada to Treat ME/CFS Patients

ORLANDO, Fla., April 04, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, said it amended its agreement with Netherlands-based myTomorrows...
April 02, 2018 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announced Financial Results for the Year Ended December 31, 2017

ORLANDO, Fla., April 02, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on immuno-pharmaceutical research and the commercial development of its immunology products...
March 14, 2018 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma and UNMC Partner to Take on Pancreatic Cancer

ORLANDO, Fla., March 14, 2018 (GLOBE NEWSWIRE) -- The University of Nebraska Medical Center and Hemispherx Biopharma, Inc. (NYSE American:HEB) are joining forces to take on pancreatic cancer, one of...
March 05, 2018 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx to Present at the 30th Annual ROTH Conference

ORLANDO, Fla., March 05, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, announced today that it will be presenting at the 30th Annual...
February 27, 2018 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx to Present at the Inaugural LD Micro Virtual Conference

ORLANDO, Fla., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, announced today that it will be presenting at the inaugural LD...
February 26, 2018 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx To Supply Ampligen for Pancreatic Cancer Patients in Canada Under Special Access Program

ORLANDO, Fla., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB) said it is expanding its partnership with myTomorrows to supply Ampligen® for pancreatic cancer...
January 31, 2018 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx’s Ampligen Highlighted in Review of Role of TLR3 Agonist Support for “Universal” Flu Immunization Development Programs

BANFF, Alberta, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB) said William Mitchell, MD, PhD*, Professor of Pathology, Microbiology & Immunology at Vanderbilt...
January 29, 2018 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx to Present at the BIO CEO & Investor Conference

ORLANDO, Fla., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, announced today that it will be presenting at the BIO CEO &...
January 26, 2018 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Announces Presentation on the Potential Role of Ampligen as an Immune System Amplifier Improving Seasonal Flu Vaccine Cross-Protection

ORLANDO, Fla., Jan. 26, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, announces that William Mitchell, MD, PhD, Professor of Pathology,...